Australian pharma patentees now face an uphill battle to obtain interlocutory injunctions
The tide has turned against rights holders in recent years, write Gavin Adkins and Jacqueline Simpkin of Griffith Hack – though an accompanying trend of expedited trials offers some consolation
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.